When referring patients for denosumab or intravenous iron infusions, please be aware of the significant risk of severe hypocalcaemia and hypophosphataemia, particularly if these therapies are administered concurrently or in close succession. To minimise risk, a minimum 3-month interval between denosumab and IV iron infusions is recommended. Baseline assessment and correction of serum calcium, phosphate, magnesium, vitamin D, and renal function are essential, with ongoing monitoring post-infusion. Extra caution is warranted in high-risk groups, and all members of the patient’s care team should be informed. For detailed clinical recommendations, including pre-treatment assessment, monitoring, and management strategies, please refer to the full information sheet available to download and print.
Guidelines for Referrers – Denosumab and Intravenous Iron Infusions
Site design by 
